I. GOALS

The goals of the REMS for TRUVADA for a Pre-Exposure Prophylaxis (PrEP) Indication are:

To inform and educate prescribers and uninfected individuals at high risk for acquiring HIV-1 infection about:

- The importance of strict adherence to the recommended dosing regimen
- The importance of regular monitoring of HIV-1 serostatus to avoid continuing to take TRUVADA for a PrEP indication, if seroconversion has occurred, to reduce the risk of development of resistant HIV-1 variants
- The fact that TRUVADA for a PrEP indication must be considered as only part of a comprehensive prevention strategy to reduce the risk of HIV-1 infection and that other preventive measures should also be used
II. REMS ELEMENTS

A. Medication Guide

A TRUVADA Medication Guide will be dispensed with each TRUVADA prescription in accordance with 21 CFR 208.24.

The Medication Guide is part of the REMS and is appended.

B. Elements to Assure Safe Use

1. Gilead Sciences, Inc. (Gilead) will ensure that training and education through the TRUVADA for a PrEP Indication Healthcare Provider Education Program is available to healthcare providers (HCPs) who prescribe TRUVADA for a PrEP indication.

   a. Gilead will ensure that training and education materials will be available for completion by HCPs who prescribe TRUVADA for a PrEP indication via the TRUVADA for a PrEP Indication Healthcare Provider Education Program on the REMS website (www.TRUVADApreprems.com) or via hard copy available upon request. This information will remain on the REMS website for a period of 3 years from initial approval.

   b. Gilead will ensure that prescribers can report that they have completed the TRUVADA for a PrEP Indication Healthcare Provider Education Program online or via a postage paid business reply card.

   c. Gilead will maintain a secure database with a list of HCPs who have completed the prescribers training.

   d. Gilead’s training efforts will target the following HCPs who are likely to prescribe TRUVADA for a PrEP indication:

      • Primary care physicians, including internal medicine, family practice, and general medicine physicians

      • Infectious Diseases specialists

      • Obstetrician-gynecologists

      • Addiction specialists

   e. In order to facilitate prescriber training and education, Gilead will disseminate information about the potential and known safety risks with TRUVADA for a PrEP indication to select professional organizations representing the HCPs likely to prescribe TRUVADA for a PrEP indication as described in d. above.
i. The Safety Information Fact Sheet for Prescribers about TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication will be available for distribution on the TRUVADA for a PrEP Indication REMS website or via hard copy for select professional organizations to disseminate to HCPs bi-annually, for 3 years.

ii. The Safety Information Fact Sheet for Prescribers About TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication will include:

- The importance of strict adherence to the recommended dosing regimen
- The importance of regular monitoring of HIV-1 serostatus to avoid continuing to take TRUVADA for a PrEP indication, if seroconversion has occurred, to reduce the risk of development of resistant HIV-1 variants
- The fact that TRUVADA for a PrEP indication must be considered as only part of a comprehensive prevention strategy to reduce the risk of HIV-1 infection and that other preventive measures should also be used

iii. Within 60 days of product approval or at the time of product launch, whichever is sooner, and again at 6, 12, and 24 months, Gilead will send the Safety Information Fact Sheet to the following professional organizations:

- HIV Medicine Association/Infectious Diseases Society of America
- American Academy of HIV Medicine
- Association of Nurses in AIDS Care
- National Medical Association
- American Academy of Family Physicians
- American Society of Addiction Medicine
- American College of Obstetricians and Gynecologists
- National Association of Community Health Centers
- National Association of City and County Health Officials
- American College of Preventive Medicine
- National Association of Public Hospitals
• American Pharmacists Association

The Safety Information Fact Sheet for Prescribers about TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication will be provided to MedWatch at the same time it is provided to these professional organizations.

The Safety Information Fact Sheet for Prescribers about TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication is part of the REMS and is appended.

d. In order to facilitate prescriber training and education, Gilead will disseminate printed safety information (above) about the use of TRUVADA for a PrEP indication to target HCPs through select professional scientific journals:

i. Journal information pieces will be published quarterly as printed information in the following professional society journals for 3 years following initial approval of the REMS:

- Journal of the American Medical Association
- Journal of the Academy of Family Physicians
- Obstetricians and Gynecologists
- Clinical Infectious Diseases
- New England Journal of Medicine

The journal information piece is part of the REMS and is appended

g. Gilead will ensure that, as part of training and education, the following materials are available to HCPs:

i. **Dear Healthcare Provider (DHCP) letter** will include the potential and known risks associated with the use of TRUVADA for a PrEP indication and explain how to access the relevant training and education materials provided by Gilead. The letter will be sent to HCPs who are likely to prescribe TRUVADA for a PrEP indication, as described in d. above. The letter will be sent within 60 days of product approval or at the time of product launch, whichever is sooner, and again after 6, 12 and 24 months. The Prescribing Information and Medication Guide will also be available with the DHCP letter. The letter will be available on the TRUVADA for a PrEP Indication REMS website on the date of the first mailing.

Gilead will distribute the DHCP letter to the targeted HCPs via electronic mail, mail, or facsimile.
ii. **Important Safety Information about TRUVADA for a PrEP Indication for Healthcare Providers** and **Important Safety Information about TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus-1 (HIV-1) Infection** will include both information directed to prescribers for education, as well as safety risk information for prescribers to use to educate uninfected individuals considering or taking TRUVADA for a PrEP indication.

iii. Prescribers will have access to the **Agreement Form for Initiating TRUVADA for Pre-Exposure Prophylaxis (PrEP)** to be discussed with an uninfected individual taking TRUVADA for a PrEP indication. The Agreement Form will be for use at each visit to facilitate discussion of and promote understanding about the safety risks associated with the use of TRUVADA for a PrEP indication, the importance of adherence to the recommended daily dosing regimen, monitoring HIV-1 test results, and screening for sexually transmitted infections. The prescriber and the uninfected individual will sign the Agreement Form and the form will be placed in the individual’s medical record.

iv. Prescribers will have access to a **Checklist for Prescribers: Initiation of TRUVADA for Pre-exposure Prophylaxis (PrEP)** as a reminder for the management of an uninfected individual considering or taking TRUVADA for a PrEP indication, recommendations for screening laboratory test results including a negative HIV-1 test result, sexually transmitted infections, signs and symptoms of acute HIV-1 infection and hepatitis B, vaccination, as needed, to ensure a comprehensive prevention strategy for prescribing TRUVADA for a PrEP indication in an uninfected individual.

v. The posting on the REMS Website for TRUVADA for a PrEP Indication and/or a mailing will include the TRUVADA for a PrEP Indication Healthcare Provider Training and Education Program which will consist of the following materials to support the training and educational process:

1. Prescribing Information
2. Medication Guide
3. Dear Healthcare Provider Letter
4. Training Guide for Healthcare Providers
5. Healthcare Provider Education Slide Deck
6. Important Safety Information about TRUVADA for a PrEP Indication for Healthcare Providers

Reference ID: 3526740
7. Important Safety Information about TRUVADA to Reduce the Risk of Getting Human Immunodeficiency Virus-1 (HIV-1) Infection

8. Agreement Form for Initiating TRUVADA for Pre-Exposure Prophylaxis (PrEP)

9. Checklist for Prescribers: Initiation of TRUVADA for Pre-exposure Prophylaxis (PrEP) to manage an uninfected individual considering or taking TRUVADA for a PrEP indication

10. Safety Information Fact Sheet for Prescribers about TRUVADA for a Pre-exposure Prophylaxis (PrEP) Indication

These materials are part of the REMS and are appended.

h. Gilead will ensure that all materials listed in or appended to the TRUVADA for a PrEP Indication program will be available through the TRUVADA REMS program website, www.truvadapreprems.com, within 30 days of the most recent REMS modification approval. This information will remain on the website for a period of 3 years from product approval.

C. Timetable for Submission of Assessments

Gilead Sciences, Inc. will submit REMS Assessments to FDA annually from the initial date of the approval (07/16/12) of the REMS for the first year and every 18 months, thereafter. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Gilead Sciences, Inc. will submit each assessment so that it will be received by the FDA on or before the due date.